Physician profile
Monica E Mazda
NPI 1770718116
$8,442.89
in general payments reported to CMS, 2019-2025
64 companies · $1,425 in 2025
The $1,425 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,465 · 2020: $607 · 2021: $1,213 · 2022: $879 · 2023: $1,256 · 2024: $1,597 · 2025: $1,425.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,278.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,278.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,125.70 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $887.10 | 2019-2025 | |
| Biogen, INC. | $810.74 | 2019-2025 | Vumerity, Tysabri, Avonex |
| Pfizer INC. | $416.67 | 2022-2025 | |
| Livanova USA, INC. | $367.01 | 2019-2025 | Vns Therapy Sentiva Model 1000 Generator |
| Eisai INC. | $290.71 | 2019-2023 | |
| Ucb, INC. | $285.84 | 2020-2025 | Briviact, Nayzilam, Rystiggo |
| Jazz Pharmaceuticals INC. | $259.55 | 2019-2025 | Xywav |
| Argenx US, INC. | $244.72 | 2022-2025 | Vyvgart |
| Neurocrine Biosciences, INC. | $235.28 | 2019-2025 | Ingrezza, Ongentys |
| Csl Behring | $210.60 | 2019-2025 | Hizentra |
| Lilly USA, LLC | $198.56 | 2019-2024 | Kisunla, Amyvid |
| Mdd US Operations, LLC | $190.52 | 2019-2025 | Apokyn |
| Genzyme Corporation | $153.57 | 2019-2025 | |
| Emd Serono, INC. | $137.93 | 2019-2025 |
Show all 64 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Monica Mazda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.